 NEW YORK, June 14, 2021 GLOBE NEWSWIRE -- Anavex Life Sciences Corp. Anavex or the Company Nasdaq: AVXL, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system CNS diseases, today reported that ANAVEX2-73 blarcamesine and ANAVEX3-71 AF710B are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets , titled The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimers.1 